EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

T2-Low Asthma in Women: A Clinically Relevant Distinct Endotype

Ching Yan Cheung, Wang Chun Kwok

SN Comprehensive Clinical Medicine · 20.10.2026 · 8 (1)

DOI: 10.1007/s42399-026-02788-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 20.10.2026. Verfasst von Ching Yan Cheung und 1 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 (T2)-low asthma is a heterogeneous endotype associated with neutrophilic or paucigranulocytic airway inflammation, reduced corticosteroid responsiveness, and poorer clinical outcomes. Selected T2-low-associated asthma phenotypes—particularly late-onset disease, obesity-associated asthma, and menopause-associated asthma—are more frequently observed in women, suggesting that sex-specific biological and environmental factors influence disease expression. This review synthesizes the current evidence on the determinants of T2-low asthma in women, with a focus on epidemiology, pathophysiological mechanisms, and therapeutic implications.

Methods

PubMed, Embase, and Scopus were searched for English-language articles published up to July 2026. Search terms included keywords related to T2-low asthma, sex differences, reproductive factors, obesity, and smoking.

Results

The reported prevalence of T2-low asthma varies from 14% to 50% with neutrophilic asthma accounting for 20% to 30% of patients. In women, estrogen signaling and hormonal variability across the menstrual cycle and menopause may contribute to T helper 17 (Th17)-skewed neutrophilic inflammation, while obesity and smoking may exacerbate disease severity and reduce corticosteroid sensitivity. Management includes weight reduction, smoking cessation, comorbidity optimization, and selected add-on therapies, including macrolides, long-acting muscarinic antagonists (LAMAs), tezepelumab, and novel therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) in obesity-associated asthma.

Conclusions

The absence of validated positive biomarkers remains a critical barrier to accurate diagnosis, patient stratification, and targeted therapy development. Important limitations include heterogeneous study populations and predominantly observational data. Improved understanding of sex-specific influences on T2-low asthma may enhance recognition and guide personalized therapeutic strategies, reducing disease burden in this underserved population.

Zitieren

APA

Cheung, C. Y., & Kwok, W. C. (2026). T2-Low Asthma in Women: A Clinically Relevant Distinct Endotype. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02788-9

Vancouver

Cheung CY, Kwok WC. T2-Low Asthma in Women: A Clinically Relevant Distinct Endotype. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02788-9

BibTeX
@article{Cheung2026,
  author = {Cheung, Ching Yan and Kwok, Wang Chun},
  title = {T2-Low Asthma in Women: A Clinically Relevant Distinct Endotype},
  journal = {SN Comprehensive Clinical Medicine},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1007/s42399-026-02788-9}
}
Kostenlos starten →